MedTrace Logo

SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

NCT05547451 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2024-06-21

No results posted yet for this study

Summary

Since june 2021, vaccination against the SARS-Cov2 virus is recommanded in France to all children from 12 to 18 years old. In the specific population of teenagers living with juvenile arthritis, the vaccine seems to be safe and well tolerated. It has been shown previously that this population has a vaccine coverage lower than the global population even though few datas are available on this topic The aim of this resarch is to study the vaccination coverage against the SARS-Cov2 virus and more specifically the reasons why adolescents were or were not vaccinated in the population of adolescents with juvenile arthitis followed up in Angers, Nantes and Rennes. For this purpose, a review of the medical record will be done and a questionnaire will be adressed to the family of patients in order to collect informations about the disease, the treatments, the motives or obstacles to vaccination. Secondaries end points are safety of the vaccination, consequences on the juvenile arthritis (such as changes in the medication, flare-up of the illness) and the occurence of covid infection after vaccination.

Conditions

  • SARS Cov 2 Vaccination in Adolescents With Juvenile Idiopathic Arthritis

Sponsors & Collaborators

  • University Hospital, Angers

    collaborator OTHER_GOV

  • Rennes University Hospital

    collaborator OTHER

  • Clinique de l'Anjou

    collaborator OTHER

  • Nantes University Hospital

    lead OTHER

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-09
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05547451 on ClinicalTrials.gov